UBS initiated coverage of Kissei Pharmaceutical (KSPHF) with a Neutral rating and 4,900 yen price target The firm says the company’s business stability is priced into the shares with limited catalysts ahead.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KSPHF:
- Kissei Pharmaceutical Adjusts Dividend Payment Date
- Kissei Pharmaceutical Co Reports Growth Amid Increased R&D Investment
- Kissei Pharmaceutical Revises Financial Forecast with Positive Outlook
- Kissei Pharmaceutical Reports Financial Results with Increased Net Sales
- Kissei Pharmaceutical Co (KSPHF) Q2 Earnings Cheat Sheet